Creo Medical Share Discussion Threads

[mikeh30] 12/1/2024 11:47

50ma now just under 38Between 40 and 42 is the next area to test before the next move up

[bloomberg2] 12/1/2024 08:06

No waiting for upload on utube

[wan] 12/1/2024 07:45

Intuitive is guiding for growth in procedures, robotic placements, and revenues -

Intuitive CEO: Strong robot placements offset bariatric surgery slowdown
Speaking at the J.P. Morgan Healthcare Conference, CEO Gary Guthart said the robotics company is also seeing strong growth in general surgeries.

Published Jan. 11, 2024

the robotic surgery leader is also seeing strong system placements and growth in general surgeries, CEO Gary Guthart told investors at the J.P. Morgan Healthcare Conference in San Francisco. The company preannounced that overall procedures assisted by its da Vinci robot grew 21% in the fourth quarter, above analysts’ expectations. The momentum prompted Intuitive to forecast an increase of about 13% to 16% in da Vinci procedures worldwide in 2024.

In 2023, Intuitive’s da Vinci procedure growth was 22%, as almost 2.29 million surgeries were performed with the systems.

The company placed 415 da Vinci robots with customers in the fourth quarter alone, up 12% from the same period a year ago. Preliminary fourth-quarter revenue rose 17% to about $1.93 billion.

William Blair analyst Brandon Vazquez said the preliminary fourth-quarter results beat expectations in nearly all categories. “The bottom line is that Intuitive is clearly heading into 2024 with strong momentum,” Vazquez said in a report to clients.
Full story -

Staying with Creo's growing collaboration with robotic surgery companies, notably with Intuitive, the world's largest robotic surgery company -


The following, also from the above Medtechdive link, provides food for thought -
At the J.P. Morgan event, Guthart declined to say whether Intuitive plans to roll out a next-generation multi-port robot in the year ahead, a topic of interest among investors.

“The fact that management didn’t comment leaves open the possibility for a launch this year,” J.P. Morgan analyst Robbie Marcus said in a research note after the presentation, pointing out that the executives made clear last year a new robot would not come in 2023.

[hatfullofsky] 12/1/2024 07:39

Did you join ? Anything of note ?

[bloomberg2] 11/1/2024 14:05

https://www.proactiveinvestors.co.uk/register/event_details/436

[bloomberg2] 11/1/2024 13:59

And a proactive presentation tonight!! Should be an interesting watch

[master investor] 11/1/2024 13:04

The markets were very poor over last 18 months for the reasons mentioned earlier. A lot of money left AIM as fear set in and people were scared to leave their cash in the market. Baillie Gifford selling down was probably the biggest reason the chart looks like it does. A persistent seller in a bear market moved the share price down. There are no swings on the chart from 100p to 18p. It's a different story now. Some very encouraging rns over the last few months. An over subscribed raise. Directors putting 2 million pounds of their own money in (you don't see this very often). Now fully funded into 2025 with FDA and European approval and of course NICE selecting speedboat for review. We have almost certainly seen institutional buying looking at the trades over the last few weeks. I will be amazed If we are not trading above 100p in the next 6 months and a sale of the company seems inevitable.

[dr biotech] 11/1/2024 08:20

Covid played a part, operations and regulatory progress wasn’t happening and the ongoing costs remained, hence cash ran low doubts rose as a going concern and the share price eroded over time.

[bihas2019] 11/1/2024 07:53

Think there were a few factors
-general market sentiment, risk of recession, wars etc
- everyone knew creo needed to raise more funds causing share price to drift downwards, management in my opinion left it too long to raise
-Baillie Gifford (a significant shareholder) had issues and I believe this forced their hand to sell down shares
-inflation was high, as are interest rates which mean people were using higher discount rates when calculating company valuations, this decreases company valuations and encourages some people to sell

[master investor] 10/1/2024 22:51

Look what happened to a lot of solid companies such as HVO at the the end of the bull run. From mid 40s down to sub 10p. The Russian invasion of Ukraine pushed most stocks down. Excellent to see many of the good companies share price bounce back over last couple of months.

[bloomberg2] 10/1/2024 20:42

Nothing other than increasing costs and a placing of £1.82 ! And probably the ending of the Covid bull run back in the summer of 2021!!

[arab3] 10/1/2024 20:06

what caused the drops from 200 before ?

[master investor] 10/1/2024 20:01

I think a little higher but would take 180p

[bloomberg2] 10/1/2024 19:14

Let's all agree on £1.80 then !!

[master investor] 10/1/2024 16:45

I think you have your sights set a little low there.

[bloomberg2] 10/1/2024 15:36

I'd take 90P

[master investor] 10/1/2024 14:49

Agree, some massive buys coming in Iver last 2 days. Over 3m shares bought in 7 transactions. Institution loading up or take over imminent?

[cyberbub] 10/1/2024 12:32

You might be waiting a while, they have money for at least another year.

[porky9] 10/1/2024 11:43

I will most likely take some in the next placing, love the tech, they need to get this towards BE point. Hoping it’s just the one further placing required.

[dr biotech] 10/1/2024 11:30

Takeover seems most likely positive outcome for me - not only will they have patent protection but they also have regulatory approval protection too. Biggest question mark is getting sufficient traction with customers before the money runs out (or low). If they can reach profitability on schedule it will be a big winner.

[cyberbub] 10/1/2024 11:29

Exactly. The valuation of CREO today is high based on their current financials, but it's quite clear that major commercial traction for their high-margin surgical products is only a matter of time.A takeover at well over 100p, possibly 200p even (still small beer for Intuitive or a.n.other major player) is very probable in the next 12-18 months IMHO.And not forgetting that Creo have a large stable of other patents which they're not exploiting yet.GLA NAI

[robe7] 10/1/2024 11:12

Hoping the Patents are water tight because this looks like a winner - Intuitive or a larger firm will buy CREO out rather than come up with a similar devices themselves.

[bloomberg2] 10/1/2024 11:09

In BED with Intuitive !!

[master investor] 10/1/2024 11:01

Just think of the repeat orders.

[dr biotech] 10/1/2024 10:49

It does seem to be an excellent device that so far has produced improved outcomes, at least on a casual basis. Concerns for me is how much hand holding will be required to sell it and the cost/time involved in this - did they have to fly a team out to Equador to do this?

Still heading in the right direction.